Small molecule intercalation with double stranded DNA: implications for normal gene regulation and for predicting the biological efficacy and genotoxicity of drugs and other chemicals.

The binding of small molecules to double stranded DNA including intercalation between base pairs has been a topic of research for over 40 years. For the most part, however, intercalation has been of marginal interest given the prevailing notion that binding of small molecules to protein receptors is largely responsible for governing biological function. This picture is now changing with the discovery of nuclear enzymes, e.g. topoisomerases that modulate intercalation of various compounds including certain antitumor drugs and genotoxins. While intercalators are classically flat, aromatic structures that can easily insert between base pairs, our laboratories reported in 1977 that a number of biologically active compounds with greater molecular thickness, e.g. steroid hormones, could fit stereospecifically between base pairs. The hypothesis was advanced that intercalation was a salient feature of the action of gene regulatory molecules. Two parallel lines of research were pursued: (1) development of technology to employ intercalation in the design of safe and effective chemicals, e.g. pharmaceuticals, nutraceuticals, agricultural chemicals; (2) exploration of intercalation in the mode of action of nuclear receptor proteins. Computer modeling demonstrated that degree of fit of certain small molecules into DNA intercalation sites correlated with degree of biological activity but not with strength of receptor binding. These findings led to computational tools including pharmacophores and search engines to design new drug candidates by predicting desirable and undesirable activities. The specific sequences in DNA into which ligands best intercalated were later found in the consensus sequences of genes activated by nuclear receptors implying intercalation was central to their mode of action. Recently, the orientation of ligands bound to nuclear receptors was found to match closely the spatial locations of ligands derived from intercalation into unwound gene sequences suggesting that nuclear receptors may be guiding ligands to DNA with remarkable precision. Based upon multiple lines of experimental evidence, we suggest that intercalation in double stranded DNA is a ubiquitous, natural process and a salient feature of the regulation of genes. If double stranded DNA is proven to be the ultimate target of genomic drug action, intercalation will emerge as a cornerstone of the future discovery of safe and effective pharmaceuticals.

[1]  V. Mahesh,et al.  Stereochemical complementarity of progesterone and cavities between base pairs in partially unwound double stranded DNA using computer modeling and energy calculations to determine degree of fit , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  A. Lehner,et al.  The stereochemical complementarity of DNA and reproductive steroid hormones correlates with biological activity. , 1986, Journal of steroid biochemistry.

[3]  M. Lebwohl,et al.  DNA structural integrity and base composition affect ultraviolet light-induced oxidative DNA damage. , 1998, Biochemistry.

[4]  F. Crick,et al.  Genetical Implications of the Structure of Deoxyribonucleic Acid , 1953, Nature.

[5]  M. Orozco,et al.  Effect of Bulky Lesions on DNA , 2004, Journal of Biological Chemistry.

[6]  D. Brann,et al.  Emerging diversities in the mechanism of action of steroid hormones , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[7]  V. Mahesh,et al.  ANDROGENIC ACTIVITY OF ANTIANDROGENS PREDICTED BY FIT INTO DNA , 1994, American Journal of Therapeutics.

[8]  E. D. Bransome,et al.  The ligand insertion hypothesis in the genomic action of steroid hormones 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997. , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  Rajan P Kulkarni,et al.  Structure-function correlation of chloroquine and analogues as transgene expression enhancers in nonviral gene delivery. , 2006, Journal of medicinal chemistry.

[10]  Ronald D Snyder,et al.  Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. , 2002, Mutation research.

[11]  R. Snyder,et al.  Toward a greater appreciation of noncovalent chemical/DNA interactions: Application of biological and computational approaches , 2005, Environmental and molecular mutagenesis.

[12]  V. Mahesh,et al.  A putative step in steroid hormone action involves insertion of steroid ligands into DNA facilitated by receptor proteins , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  H. Tajmir-Riahi,et al.  Diethylstilbestrol-DNA Interaction Studied by Fourier Transform Infrared and Raman Spectroscopy , 1996, The Journal of Biological Chemistry.

[14]  S. Shibutani,et al.  Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. , 2004, Cancer research.

[15]  R. Snyder,et al.  EVIDENCE FOR AND ROLE OF THE DIMETHYLAMINO GROUP IN TAMOXIFEN DNA INTERCALATION IN INTACT CHINESE HAMSTER V79 CELLS , 2002, Drug and chemical toxicology.

[16]  J. Copland,et al.  Antiestrogenic piperidinediones designed prospectively using computer graphics and energy calculations of DNA-ligand complexes , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  M. Ariatti,et al.  Low Concentrations of Chlorpromazine and Related Phenothiazines Stimulate Gene Transfer in HeLa Cells Via Receptor-Mediated Endocytosis , 2002, Drug delivery.

[18]  D. Patel,et al.  Molecular recognition in the FMN-RNA aptamer complex. , 1996, Journal of molecular biology.

[19]  Ronald D Snyder,et al.  Evaluation of DNA intercalation potential of pharmaceuticals and other chemicals by cell‐based and three‐dimensional computational approaches , 2004, Environmental and molecular mutagenesis.

[20]  M. Jann,et al.  Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. , 1992, Clinical pharmacy.

[21]  E. Desombre,et al.  Cytotoxicity of 125 I-oestrogen decay in non-oestrogen receptor-expressing human breast cancer cells, MDA-231 and oestrogen receptor-expressing MCF-7 cells , 2001 .

[22]  V. Mahesh,et al.  Multidimensional screening and design of pharmaceuticals by using endocrine pharmacophores , 1999, Steroids.

[23]  J. Essigmann,et al.  Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents. , 2004, Bioorganic & medicinal chemistry letters.

[24]  A. Wang,et al.  Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy. , 1997, Biochemistry.

[25]  Jarboe Ch,et al.  Structural aspects of picrotoxinin action. , 1968 .

[26]  R. Snyder,et al.  The influence of N-dialkyl and other cationic substituents on DNA intercalation and genotoxicity. , 2005, Mutation research.

[27]  J. Copland,et al.  Design of novel antiestrogens , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  J. Mcchesney,et al.  Simple analogs of the toxin callicarpone. , 1979, Journal of pharmaceutical sciences.

[29]  M. Jansen,et al.  Advances in DNA-ligands with groove binding, intercalating and/or alkylating activity: chemistry, DNA-binding and biology. , 2005, Current medicinal chemistry.

[30]  L. Hendry Stereochemical complementarity of DNA and steroid agonists and antagonists , 1988 .

[31]  J. Bolton,et al.  Equine estrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. , 2001, Chemical research in toxicology.

[32]  H. Greim,et al.  Cyproterone acetate induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in gamma-glutamyltranspeptidase-positive cells. , 1992, Carcinogenesis.

[33]  Qian-qian Zhang,et al.  Synthesis, crystal structure and DNA binding studies of a binuclear copper(II) complex with phenanthroline. , 2006, Journal of inorganic biochemistry.

[34]  W. Shepard,et al.  Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site. , 1999, Nucleic acids research.

[35]  I. Vilfan,et al.  Characterization of ciprofloxacin binding to the linear single- and double-stranded DNA. , 2003, Biochimica et biophysica acta.

[36]  William R. Kobertz,et al.  An intercalation inhibitor altering the target selectivity of DNA damaging agents: synthesis of site-specific aflatoxin B1 adducts in a p53 mutational hotspot. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Steven R Tannenbaum,et al.  DNA adducts formed by a novel antitumor agent 11β-dichloro in vitro and in vivo , 2006, Molecular Cancer Therapeutics.

[38]  Diana C. Roe,et al.  Finding potential DNA-binding compounds by using molecular shape , 1994, J. Comput. Aided Mol. Des..

[39]  C. Huggins,et al.  Induction and extinction of mammary cancer. A striking effect of hydrocarbons permits analysis of mechanisms of causes and cure of breast cancer. , 1962, Science.

[40]  A W Schwartz,et al.  The case for an ancestral genetic system involving simple analogues of the nucleotides. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Jerina,et al.  Crystal structure of a benzo[a]pyrene diol epoxide adduct in a ternary complex with a DNA polymerase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Karen L. Buchmueller,et al.  Synthesis and Evaluation of an Intercalator–Polyamide Hairpin Designed to Target the Inverted CCAAT Box 2 in the Topoisomerase IIα Promoter , 2006 .

[43]  V. Mahesh,et al.  Stereochemical complementarity of progesterone, RU486 and cavities between base pairs in partially unwound double stranded DNA assessed by computer modeling and energy calculations , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[44]  Tunable DNA Cleavage by Intercalating Peptidoconjugates , 2006, Chembiochem : a European journal of chemical biology.

[45]  L. Hendry,et al.  Gene Regulation: The Involvement of Stereochemical Recognition in DNA-Small Molecule Interactions , 2015, Perspectives in biology and medicine.

[46]  G. Thomas,et al.  The complex of ethidium bromide with genomic DNA: structure analysis by polarized Raman spectroscopy. , 2007, Biophysical journal.

[47]  Yuzhong Zhang,et al.  Electrochemical studies oxidation of ciprofloxacin at nano-SnO2/PVS modified electrode and its interaction with calf thymus DNA. , 2007, Frontiers in bioscience : a journal and virtual library.

[48]  Colin G. Barry,et al.  Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. , 2004, Current topics in medicinal chemistry.

[49]  L B Hendry,et al.  Drug Design with a New Type of Molecular Modeling Based on Stereochemical Complementarity to Gene Structure , 1993, Journal of clinical pharmacology.

[50]  C. W. Andrews,et al.  DNA intercalation and inhibition of topoisomerase II. Structure-activity relationships for a series of amiloride analogs. , 1989, The Journal of biological chemistry.

[51]  L. Hendry,et al.  Chirality and stereochemical recognition in DNA-phytohormone interactions: A model approach , 1978, Origins of life.

[52]  Y. Pommier,et al.  Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles. , 2006, Journal of medicinal chemistry.

[53]  Y. Pommier,et al.  Bisindenoisoquinoline Bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA Intercalator and Topoisomerase Inhibitor with Antitumor Activity , 2006, Molecular Pharmacology.

[54]  J. Schwartz,et al.  Cellular and subcellular studies of the radiation effects of Auger electron-emitting estrogens. , 1996, Acta oncologica.

[55]  J. Barton,et al.  Insights into finding a mismatch through the structure of a mispaired DNA bound by a rhodium intercalator , 2007, Proceedings of the National Academy of Sciences.

[56]  L. Hendry,et al.  Computer modeling of gibberellin-DNA binding. , 1992, Journal of theoretical biology.

[57]  N. Sidell,et al.  Transcriptional inhibition of the estrogen response element by antiestrogenic piperidinediones correlates with intercalation into DNA measured by energy calculations , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[58]  W. Guschlbauer Nucleic acid structure , 1976 .

[59]  John W. R. Schwabe,et al.  The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements , 1993, Cell.

[60]  L. Lerman,et al.  Structural considerations in the interaction of DNA and acridines. , 1961, Journal of molecular biology.

[61]  Ronald D Snyder,et al.  DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. , 2006, Mutation research.

[62]  Y. Pommier,et al.  Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. , 2005, Journal of medicinal chemistry.

[63]  E. D. Bransome,et al.  Structure — activity relationships of some unique estrogens related to estradiol are predicted by fit into dna , 1985, Steroids.

[64]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[65]  D. Patel,et al.  DNA bending and unwinding associated with actinomycin D antibiotics bound to partially overlapping sites on DNA. , 1996, Journal of molecular biology.

[66]  Ronald D Snyder,et al.  Evaluation of the clastogenic, DNA intercalative, and topoisomerase II‐interactive properties of bioflavonoids in Chinese hamster V79 cells , 2002, Environmental and molecular mutagenesis.

[67]  W. Denny,et al.  Dual topoisomerase I/II inhibitors in cancer therapy. , 2003, Current topics in medicinal chemistry.

[68]  E. D. Bransome,et al.  Gene based pharmacophores for drug design , 2001 .